Jianchun Duan
YOU?
Author Swipe
View article: Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics
Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics Open
Radiotherapy is a cornerstone of comprehensive cancer treatment, yet its efficacy and toxicity exhibit considerable interindividual variation. Recent evidence highlights the microbiome—the collective genomes and metabolic products of symbi…
View article: Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases Open
View article: The Impact of Focal Firm Digitalization on Supply Chain Resilience: A Supply Chain Collaboration Perspective
The Impact of Focal Firm Digitalization on Supply Chain Resilience: A Supply Chain Collaboration Perspective Open
In the context of a complex and volatile domestic and global environment, Chinese enterprises face frequent risks of supply chain disruption that seriously hinder their operations. The rise of the digital economy offers new opportunities t…
View article: Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies Open
Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti‐PD‐1 nanobody‐armored mesothelin‐targeting CAR‐T (NAC‐T) cells are …
View article: Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study
Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study Open
View article: RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations
RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations Open
Preclinical/clinical studies suggest that receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) inhibitors combined with immune checkpoint inhibitors (RLICi) enhance anti-tumor efficacy in lung adenocarcinoma (LUAD), yet mechanism…
View article: Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches
Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches Open
Background Small-cell lung cancer (SCLC) has limited therapeutic options beyond first-line treatment, and the efficacy of PD-1/PD-L1-based immunotherapy in this setting remains uncertain. This study evaluates the efficacy and safety of ser…
View article: Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial Open
View article: Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis
Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis Open
Gender, smoking, clinical stage, tumor size, differentiation grading, VPI, STAS and KRAS mutation affect DFS/RFS and OS of IMA patients after surgery. Identifying these factors may aid physicians in developing more individualized treatment…
View article: Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer Open
Background The aim of the present study was to compare the predictive accuracy of PD‐L1 immunohistochemistry (IHC), tissue or blood tumor mutation burden (tTMB, bTMB), gene expression profile (GEP), driver gene mutation, and combined bioma…
View article: Screening for depression and anxiety in lung cancer patients: A <scp>real‐world</scp> study using <scp>GAD</scp>‐7 and <scp>HADS</scp>
Screening for depression and anxiety in lung cancer patients: A <span>real‐world</span> study using <span>GAD</span>‐7 and <span>HADS</span> Open
Background The psychological well‐being of lung cancer patients is critical in‐patient care but frequently overlooked. Methods This study, employing a cross‐sectional, questionnaire‐based design, aimed to elucidate the prevalence of depres…
View article: Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer Open
Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and …
View article: Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer Open
View article: Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial
Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial Open
View article: Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer Open
Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical se…
View article: Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization Open
View article: Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines
Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines Open
View article: MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama
MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama Open
Background The association involving mismatch repair (MMR) genes, molecular subtype and specific immune cell group in tumor microenvironment has been focused by more recent studies. Its prognosis value in lung adenocarcinoma (LUAD) neoadju…
View article: Abnormal activation of <scp>NF‐κB</scp> and <scp>MAPK</scp> signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
Abnormal activation of <span>NF‐κB</span> and <span>MAPK</span> signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment Open
Background Osimertinib is the first‐line treatment for patients with epidermal growth factor receptor ( EGFR ) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR is in an immun…
View article: Supplementary Fig. S1-S5 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Fig. S1-S5 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Supplementary Figures 1-5
View article: Supplementary Table S1 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S1 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Details on the genes included in the 1021 gene panel in next-generation sequencing (NGS).
View article: Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Univariable and multivariable analysis of progression-free survival (PFS).
View article: Legend for the Supplementary Figures and Tables from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Legend for the Supplementary Figures and Tables from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Legend for the Supplementary Figures and Tables
View article: Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Univariable and multivariable analysis of progression-free survival (PFS).
View article: Legend for the Supplementary Figures and Tables from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Legend for the Supplementary Figures and Tables from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Legend for the Supplementary Figures and Tables
View article: Supplementary Table S1 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S1 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Details on the genes included in the 1021 gene panel in next-generation sequencing (NGS).
View article: Supplementary Fig. S1-S5 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Fig. S1-S5 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Supplementary Figures 1-5
View article: Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Baseline characteristics of patients in the exploratory group (discovery set and validation set) and the control group.
View article: Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
Baseline characteristics of patients in the exploratory group (discovery set and validation set) and the control group.
View article: Data from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Data from TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Open
T-cell receptor (TCR)–based biomarkers might predict patient response to immune checkpoint blockade (ICB) but need further exploration and validation for that use. We sequenced complementarity-determining region 3 of TCRβ chains isolated f…